Advertisement


Eric Jonasch, MD, on Von-Hippel Lindau Disease: Pazopanib Trial

2017 ASCO Annual Meeting

Advertisement

Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, discusses the largest prospective VHL disease-specific therapeutic trial performed to date, and the data that show pazopanib resulted in significant and sustained disease control for the majority of patients enrolled on the study. (Abstract 4516)



Related Videos

Bladder Cancer

Elizabeth R. Plimack, MD, on Advanced Urothelial Cancer: Expert Perspective

Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses highlights of three important abstracts on advanced and metastatic urothelial cancer presented at the 2017 ASCO Annual Meeting. (Abstracts 4501, 4503, 106)

Lung Cancer

Solange Peters, MD, PhD, on SCLC: Expert Perspective on CheckMate 032

Solange Peters, MD, PhD, of the University of Lausanne, examines the study findings on nivolumab ± ipilimumab in advanced small cell lung cancer, in the first report of a randomized expansion cohort. (Abstract 8503)

Issues in Oncology
Legislation

Xuesong Han, PhD, on Early-Stage Diagnosis and the Affordable Care Act: An Epidemiologic Study

Xuesong Han, PhD, of the American Cancer Society, discusses the Affordable Care Act and her study findings showing how implementation of the law is associated with a shift to early-stage diagnosis for all screenable cancers except prostate cancer (likely due to Task Force recommendations against routine screening). (Abstract 6521)

Solid Tumors

David M. Hyman, MD, on Larotrectinib in TRK Fusion Cancers: Trial Results

David M. Hyman, MD, of Memorial Sloan Kettering Cancer Center, discusses findings on the efficacy of larotrectinib, a selective tropomyosin receptor kinase inhibitor, in adult and pediatric cancers. (Abstract LBA2501)

Supportive Care

Jane McNeil Beith, MD, PhD, on Reducing Fear in Cancer Survivors

Jane McNeil Beith, MD, PhD, of Chris O’Brien Lifehouse, discusses long-term study results on a psychological intervention, called “Conquer Fear,” designed to reduce clinical levels of fear of cancer recurrence in breast, colorectal, and melanoma cancer survivors. (Abstract LBA10000)

Advertisement

Advertisement




Advertisement